文献速递肿瘤 PET/CT放射性药物与辐射防护

食管癌合并系统性红斑狼疮反应性淋巴结的68Ga-FAPI与18F-FDG摄取不一致

Discordant 68 Ga-FAPI and 18 F-FDG Uptake in Reactive Lymph Nodes in a Case of Esophageal Cancer and Systemic Lupus Erythematosus.
PubMed 文献 · Clin Nucl Med · 2026-05-13

一例54岁女性系统性红斑狼疮(SLE)合并远端食管鳞状细胞癌(SCC)患者,18F-FDG PET/CT显示腋窝淋巴结弥漫性摄取及双侧腹股沟、颈部和纵隔轻度摄取,食管肿瘤SUVmax 19.85;一周后68Ga-FAPI PET/CT显示腋窝淋巴结摄取可忽略但主肿瘤强摄取,淋巴结病理为反应性增生。该病例提示FAPI在区分炎症性与转移性淋巴结病变方面可能具有高特异性。

要点

  • SLE患者增大的淋巴结可呈18F-FDG高摄取,易误判为转移。
  • 同一患者68Ga-FAPI在反应性增生淋巴结中摄取可忽略。
  • FAPI可能有助于区分炎症性与转移性淋巴结病变。

核心结论

  • 在SLE合并食管癌患者中,反应性增生淋巴结可表现为18F-FDG摄取而68Ga-FAPI摄取可忽略,提示FAPI可能有助于区分炎症与转移。

研究设计与样本

  • 本文为单例病例报告,描述一例54岁女性SLE合并远端食管SCC患者的18F-FDG与68Ga-FAPI PET/CT表现及淋巴结病理结果。

主要发现

  • 18F-FDG PET/CT显示腋窝增大淋巴结弥漫性摄取,双侧腹股沟、颈部和纵隔轻度摄取,食管肿瘤SUVmax 19.85。
  • 一周后68Ga-FAPI PET/CT显示腋窝淋巴结摄取可忽略,主肿瘤强摄取。
  • 淋巴结组织病理学显示反应性增生。

临床怎么用

  • 对SLE等炎症性疾病患者,18F-FDG PET/CT淋巴结高摄取需谨慎解读,可考虑68Ga-FAPI协助鉴别炎症与转移。

局限性

  • 单例病例报告,结论需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This case is a 54-year-old woman with systemic lupus erythematosus (SLE) and distal esophageal squamous cell carcinoma (SCC) who showed inconsistent uptake patterns on 18 F-FDG and 68 Ga-FAPI PET/CT. 18 F-FDG PET/CT revealed diffuse uptake in the enlarged axillary lymph nodes as well as mild increased uptake in the bilateral inguinal and cervical, and mediastinal uptake, beyond the uptake in the esophageal tumor (SUVmax 19.85). A week later, FAPI PET/CT showed negligible uptake in the axillary nodes but strong uptake in the main tumor. These lymph nodes' histopathology showed reactive hyperplasia. This pattern of 18 F-FDG PET/CT has been previously described in a few cases of SLE patients mimicking lymphoma; however, this case also underscores the potential high specificity of FAPI in distinguishing inflammatory from metastatic lymph node disease.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Miralai A, Ghaedian T, Sadra H, et al. Discordant 68 Ga-FAPI and 18 F-FDG Uptake in Reactive Lymph Nodes in a Case of Esophageal Cancer and Systemic Lupus Erythematosus. Clin Nucl Med. 2026. PMID: 42149626. doi:10.1097/RLU.0000000000006541

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。